Blood Test May Detect Fatal Brain Disease in Living Patients

A new study shows for the first time that a blood test could help identify advanced stages of a devastating brain disease found to be rampant among former professional football players. Currently, the condition, chronic traumatic encephalopathy (CTE), can only be diagnosed after death.

The study is led by Boston University with participation from researchers at 20 institutions, including Gil Rabinovici , MD, from the Edward and Pearl Fein Memory and Aging Center at UC San Francisco. He serves as co-principal investigator and PET imaging lead.

The study was published in JAMA on Nov. 19 and funded by the National Institutes of Health (NIH).

CTE is characterized by mood and behavioral changes in its early stages and later by cognitive impairment and motor symptoms. As many as 3 in 4 deceased NFL players had CTE, a study published last month found. The disease also occurs in former players of other contact sports, victims of repeated blows to the head, and military veterans exposed to blast waves from explosives.

In the study, researchers analyzed blood samples taken before death from 21 former American football players who participated in previous studies. Autopsies later showed that 18 of the 21 had CTE: 16 had high-stage disease and two had low-stage disease.

Researchers measured the protein eMTBR-tau in blood samples collected while the participants were alive and compared those levels with presence of CTE when their donated brains were examined after death.

Blood levels of eMTBR-tau were significantly higher among participants with high-stage CTE than those with low-stage or no CTE. The study did not show a clear difference between low-stage CTE and no CTE, and it was too small to establish the test's diagnostic accuracy in individual patients.

Positive blood tests may result in trials with tau-targeting drugs

While these findings are "very preliminary," if validated in follow-up studies, the blood test could be used "to support a diagnosis of CTE in people who have had repetitive head impacts and are experiencing neurological symptoms," said Rabinovici, who holds the Edward and Pearl Fein Distinguished Professorship in Memory and Aging.

"In the right clinical context, a positive blood test could be used as an inclusion criterion for testing new drugs, which is especially exciting in light of the major advances in tau-targeting therapies," Rabinovici added, referring to drugs in development to treat Alzheimer's disease and other dementias.

"Ultimately, our hope is that earlier and more precise detection will help us match patients with the right treatments at the right time and improve outcomes," said corresponding author Michael Alosco, PhD, from Boston University CTE Center and Alzheimer's Disease Research Center.

Four of the participants with CTE also had Alzheimer's disease-related brain changes, and eMTBR-tau levels were highest in this group. The researchers also measured p-tau217, a blood biomarker associated with Alzheimer's disease, to help distinguish between the two diseases. Higher blood levels of eMTBR-tau were associated with a greater burden of abnormal tau in brain regions affected by CTE at autopsy, while p-tau217 was not.

If validated, the two blood tests could eventually be used together: elevated eMTBR-tau with low p-tau217 might point toward CTE, while elevations in both could indicate Alzheimer's pathology is also present.

The researchers have started recruitment in a larger validation study at UCSF, Boston University, Mayo Clinic Scottsdale, University of Florida, and University of Texas Health Science Center at San Antonio.

Participants will include up to 225 former American football players, plus 75 additional healthy participants and 50 people with Alzheimer's disease. The researchers will be looking to see if the blood test correlates with key indicators and risk factors of CTE, including head impact exposure, symptoms, brain imaging, and eMTBR-tau levels.

Authors: Co-senior author is Nicholas J. Ashton, PhD from Banner Sun Health, Banner Alzheimer's Institute, and the University of Gothenburg. First author is Annalise E. Miner of Boston University. For other researchers, please see the paper .

Funding: National Institute of Neurological Disorders and Stroke and the National Institute on Aging (R01NS122854, R01NS132290, R01NS139383, U01NS093334 and P30AG072978). For additional funding, please see the paper.

Disclosures: Please see the paper .

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.